Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study

Table 2

Summary of efficacy outcomes.

Variables, n (%)	All patients (n = 21)
	Best overall response (mRECIST)	Best overall response (RECIST v1.1)
CR	6 (28.6)	0 (0)
PR	7 (33.3)	9 (42.9)
SD	8 (38.1)	12 (57.1)
PD	0 (0)	0 (0)
ORR	13 (61.9)	9 (42.9)
DCR	21 (100)	21 (100)
DRR ≥3 months	12 (57.1)	9 (42.9)
DRR ≥6 months	10 (47.6)	8 (38.1)

CR, complete response; PR, partial response; SD, stable disease; PD, progress disease; ORR, objective response rate; DCR, disease control rate; DRR, durable response rate.